Dysfunctional Immune Development Among Infants Born to Mothers with IBD

Sponsor: UCB Pharma, Inc.

Location(s): United States


Women with Inflammatory bowel disease (IBD) and their physicians have concerns regarding the safety of biologic and immunosuppressant medication use during pregnancy. Data regarding the safety of these medications are sparse due to limited sample size at any one center and lack of uniform data collection methods. We will use a prospective cohort of pregnant women at 30 US IBD centers to determine whether the complication rates are higher among women with IBD and their offspring who are exposed to azathioprine (AZA), 6-MP, or anti-TNF agents during pregnancy compared to women with IBD who do not take these medications.